Jun 25 |
BioXcel Therapeutics' Approved Drug For Bipolar Disorders/Schizophrenia Shows No Evidence Of Worsening Or Withdrawal In Post-Marketing Study
|
Jun 25 |
BioXcel Therapeutics Announces Positive Topline Results from Post-Marketing Requirement Study Evaluating PRN Treatment of IGALMIā¢ (dexmedetomidine) Sublingual Film for Agitation Associated with Bipolar Disorders or Schizophrenia
|
May 28 |
BioXcel Therapeutics to Present at Jefferies Global Healthcare Conference
|
May 21 |
BioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
|
May 10 |
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q1 2024 Earnings Call Transcript
|
May 10 |
BioXcel Therapeutics First Quarter 2024 Earnings: Misses Expectations
|
May 10 |
Q1 2024 BioXcel Therapeutics Inc Earnings Call
|
May 9 |
BioXcel Therapeutics, Inc. (BTAI) Q1 2024 Earnings Call Transcript
|
May 9 |
BioXcel Therapeutics GAAP EPS of -$0.87 misses by $0.12, revenue of $0.58M misses by $0.05M
|
May 9 |
BioXcel Therapeutics Reports First Quarter 2024 Financial Results
|